Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Operating Margin (2016 - 2025)

Historic Operating Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 176.27%.

  • Regenxbio's Operating Margin rose 802800.0% to 176.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.04%, marking a year-over-year increase of 1955400.0%. This contributed to the annual value of 280.03% for FY2024, which is 170900.0% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Operating Margin is 176.27%, which was up 802800.0% from 296.26% recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Operating Margin ranged from a high of 78.66% in Q4 2021 and a low of 408.8% during Q1 2024
  • Its 5-year average for Operating Margin is 230.81%, with a median of 242.14% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first crashed by -2629700bps in 2022, then skyrocketed by 4224300bps in 2025.
  • Over the past 5 years, Regenxbio's Operating Margin (Quarter) stood at 78.66% in 2021, then tumbled by -334bps to 184.31% in 2022, then plummeted by -56bps to 287.68% in 2023, then increased by 16bps to 242.14% in 2024, then grew by 27bps to 176.27% in 2025.
  • Its Operating Margin stands at 176.27% for Q3 2025, versus 296.26% for Q2 2025 and 13.62% for Q1 2025.